ATE463257T1 - Zusammensetzungen zur vorbeugung und behandlung von erkältung und influenza-ähnlichen erscheinungen enthaltend ausgewählte mukadhäsive polymere - Google Patents

Zusammensetzungen zur vorbeugung und behandlung von erkältung und influenza-ähnlichen erscheinungen enthaltend ausgewählte mukadhäsive polymere

Info

Publication number
ATE463257T1
ATE463257T1 AT03810888T AT03810888T ATE463257T1 AT E463257 T1 ATE463257 T1 AT E463257T1 AT 03810888 T AT03810888 T AT 03810888T AT 03810888 T AT03810888 T AT 03810888T AT E463257 T1 ATE463257 T1 AT E463257T1
Authority
AT
Austria
Prior art keywords
compositions
influenza
cold
treatment
prevention
Prior art date
Application number
AT03810888T
Other languages
English (en)
Inventor
Jayant Ekanth Khanolkar
La Harpe Shane Michael De
Benoit Maurice Mullet
Paul John Rennie
Philip Williams
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of ATE463257T1 publication Critical patent/ATE463257T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT03810888T 2003-01-13 2003-12-23 Zusammensetzungen zur vorbeugung und behandlung von erkältung und influenza-ähnlichen erscheinungen enthaltend ausgewählte mukadhäsive polymere ATE463257T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34115603A 2003-01-13 2003-01-13
PCT/US2003/041106 WO2004064867A1 (en) 2003-01-13 2003-12-23 Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers

Publications (1)

Publication Number Publication Date
ATE463257T1 true ATE463257T1 (de) 2010-04-15

Family

ID=32770191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03810888T ATE463257T1 (de) 2003-01-13 2003-12-23 Zusammensetzungen zur vorbeugung und behandlung von erkältung und influenza-ähnlichen erscheinungen enthaltend ausgewählte mukadhäsive polymere

Country Status (12)

Country Link
EP (1) EP1583559B1 (de)
JP (1) JP2006514077A (de)
CN (1) CN1735434A (de)
AT (1) ATE463257T1 (de)
AU (1) AU2003302332A1 (de)
CA (1) CA2509775C (de)
DE (1) DE60332044D1 (de)
ES (1) ES2342935T3 (de)
MX (1) MXPA05007491A (de)
PL (1) PL379457A1 (de)
RU (1) RU2339403C2 (de)
WO (1) WO2004064867A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232868A1 (en) * 1999-10-19 2005-10-20 The Procter & Gamble Company Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
JP2006104114A (ja) * 2004-10-04 2006-04-20 Rohto Pharmaceut Co Ltd 粘膜適用組成物
US20070110676A1 (en) * 2005-11-17 2007-05-17 The Procter & Gamble Company Compositions useful for prevention and treatment of common cold and influenza-like symptoms
GB0602325D0 (en) * 2006-02-06 2006-03-15 Remedy Res Ltd Virucidal compositions and uses
BRPI0710654B1 (pt) 2006-04-21 2021-11-03 Toko Yakuhin Kogyo Kabushiki Kaisha Preparação de adesivo para pele/mucosa do tipo gel, pulverizável, e sistema de administração usando a preparação
EP2217279B1 (de) 2007-11-21 2017-11-01 The Procter & Gamble Company Zubereitungen zur behandlung von husten
IT1400721B1 (it) * 2010-07-07 2013-06-28 Baldacci Lab Spa Composizioni a base di acido pirrolidoncarbossilico (pca) e sali metallici.
CN103284954A (zh) * 2013-06-28 2013-09-11 辽宁亿灵科创生物医药科技有限公司 惰性纤维素鼻喷剂
JP6465820B2 (ja) * 2016-01-15 2019-02-06 安井 敦司 抗菌・抗ウイルス性組成物およびこれを含む潤滑剤
EP3950338A4 (de) 2019-03-29 2022-05-04 Mitsubishi Chemical Corporation Harzzusammensetzung, film und mehrschichtstruktur
JP7771511B2 (ja) * 2019-10-30 2025-11-18 三菱ケミカル株式会社 樹脂組成物、フィルム及び多層構造体
JP7748103B2 (ja) * 2020-03-30 2025-10-02 住化エンバイロメンタルサイエンス株式会社 抗ウイルス剤
WO2021211085A1 (ru) * 2020-04-17 2021-10-21 Кумар ГУНЬЯН Способ профилактики и лечения заболеваний, вызванных вирусами, имеющими оболочку, в том числе коронавирусами(варианты) и набор фармацевтических препаратов для его осуществления
US20220133786A1 (en) * 2020-05-01 2022-05-05 Tygrus, LLC THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
CN111759851B (zh) * 2020-08-17 2021-01-26 广东盛普生命科技有限公司 单宁酸在制备抗冠状病毒的药物方面的应用
WO2022061004A1 (en) * 2020-09-16 2022-03-24 Accelerated Woundcare Research, Inc. Nasal spray compositions to suppress coronavirus and other pathogens and methods of use
WO2022061010A1 (en) * 2020-09-16 2022-03-24 Accelerated Woundcare Research, Inc. Antiviral oral composition, method of making the oral composition and oral hygiene method
CN117482279A (zh) * 2023-06-20 2024-02-02 湖南易天然医疗科技有限公司 一种雾化液体敷料及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5989535A (en) * 1997-08-15 1999-11-23 Soma Technologies Polymeric bioadhesive emulsions and suspensions and methods of treatment
CA2382985A1 (en) * 1999-10-19 2001-04-26 Jeffrey Michael Morgan Antimicrobial compositions comprising pyroglutamic acid and optionally metal salts
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations

Also Published As

Publication number Publication date
MXPA05007491A (es) 2005-09-21
CA2509775C (en) 2010-06-01
AU2003302332A1 (en) 2004-08-13
CN1735434A (zh) 2006-02-15
ES2342935T3 (es) 2010-07-19
RU2339403C2 (ru) 2008-11-27
EP1583559B1 (de) 2010-04-07
CA2509775A1 (en) 2004-08-05
EP1583559A1 (de) 2005-10-12
JP2006514077A (ja) 2006-04-27
PL379457A1 (pl) 2006-09-18
RU2005122729A (ru) 2006-01-27
DE60332044D1 (de) 2010-05-20
WO2004064867A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
ATE463257T1 (de) Zusammensetzungen zur vorbeugung und behandlung von erkältung und influenza-ähnlichen erscheinungen enthaltend ausgewählte mukadhäsive polymere
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
ZA200809250B (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
ATE392208T1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE411280T1 (de) Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
EA200601239A1 (ru) Замещённые хинолиновые соединения
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
EA200801997A1 (ru) Новые соединения
WO2009062990A3 (en) Equilibrative nucleoside transporter ent1 inhibitors
ATE482706T1 (de) Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE602004017439D1 (de) Diagnostik- und therapie- verfahren von mit c5a rezeptor verbundenen krankheiten
WO2007059356A3 (en) Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
DE502004003212D1 (de) Verbindungen, die faktor viia inhibieren
DE602005027228D1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
UA86051C2 (en) Substituted quinoline compounds
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
ATE401873T1 (de) Spermidin derivate zur behandlung chronischer neurodegerenativer krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties